XML 57 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborations and Other Arrangements (Tables)
 12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions
The table below summarizes significant milestones (deferred) capitalized for the compounds included in this collaboration:
Product Family
Milestones
(Deferred) Capitalized(1)
Trajenta(2)
$446.4 
Jardiance(3)
289.0 
Basaglar(250.0)
(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
(2) The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(3) The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:
202020192018
Basaglar$1,124.4 $1,112.6 $801.2 
Jardiance1,153.8 944.2 658.3 
Trajenta358.5 590.6 574.7 
The following table summarizes our net product revenue recognized with respect to Olumiant:
202020192018
Olumiant$638.9 $426.9 $202.5